VERRENCY
11.11.2019 13:32:04 CET | Business Wire | Press release
Global payment innovation company Verrency today announced the appointment of Dickson Chu, an accomplished payments executive and business builder, to its global advisory board.
Mr. Chu has held leadership roles at prominent companies including Paypal, Wells Fargo, Yahoo!, Living Social and Citi, and is a board director and active advisor to a number of emerging payment companies. He is currently the head of BBVA’s San Francisco office for New Digital Businesses, where he has overall BBVA group responsibility for the governance, budget and strategic direction of BBVA’s growing global portfolio of Fintech businesses.
“Verrency is a truly unique company that has significant global momentum,” said Mr. Chu. “Their innovative enabling platform can be deployed on top of existing payment infrastructure, offering a flexible, low-cost, and time efficient way for banks and financial institutions to improve their relationships with customers. They solve a global industry problem, and I’m excited to be joining Verrency where I can help David capitalise on the urgency amongst banks, processors and even super-apps to better compete for their customers around the moment of payment.”
“Dickson’s incredible fintech & payments experience, especially with financial institutions such as BBVA, PayPal and Citi are a tremendous asset as we look to expand the delivery of our patented API platform,” said David Link, Verrency Founder and CEO. “Dickson’s vision, passion and his depth of experience in precisely the area in which Verrency operates are invaluable as we continue our expansion across the United States and overseas. Dickson’s unique insights will also be instrumental as Verrency continues to expand its service offerings into data analytics and other services around the moment of payment.”
Verrency’s industrial-grade platform fits on top of a bank’s, processor’s or wallet’s existing infrastructure, opening the door for rapid delivery of enhanced features and new services without the need to change existing legacy technology or to migrate portfolios. The company has announced agreements with a number of major financial institutions around the world, including UAE-based Emirates NBD, Colombia’s Banco Davivienda, Australia's Volt Bank, and the US-based global processor FIS, among others.
Prior to BBVA, Mr. Chu was Chief Product Officer and EVP Corporate Development at Ingo Money where he was responsible for strategy, product management, strategic alliances and M&A. Ingo Money focuses on transforming consumer access to money by increasing consumer adoption of new and existing digital payment platforms.
Mr. Chu also currently serves on the boards of Simple, Azlo, Covault, Denizen, Upturn, Ingo Money, Boomtown and Opportunity Fund.
About Verrency
Verrency puts financial institutions back at the centre of innovation. Verrency's payments innovation platform helps issuers to acquire and retain customers and increase payment spend while increasing security, control and connectability. Verrency works behind the scenes to enable an ever-increasing range of value-added services for an issuer's customers quickly and easily without major changes to existing payments infrastructure or the need to integrate to point-of-sale systems. Verrency also enables rapid connection to third-party services via its extensive FinTech ecosystem with little to no integration. For more information, see www.verrency.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191111005270/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
